Laura Folgori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Folgori has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mike Sharland
Antibiotic Policy Group, School of Health and Medical Sciences, City St. George's University of London, London, United Kingdom
3 shared publications Irja Lutsar
Department of Microbiology, Faculty of Medicine, University of Tartu, Tartu, Estonia
2 shared publications- Paul Trafford Heath
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK
2 shared publications A Sarah Walker
Nuffield Department of Clinical Medicine; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
1 shared publicationA. Sarah Walker
Nuffield Department of Clinical Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, OX1 3PA, UK
1 shared publicationC. Kortsalioudaki
Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, UK
1 shared publication
Latest Publications
- Open Access
- 3 February 2020
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (S24) , 58-60
Rotavirus vaccines in clinical development: Current pipeline and state‐of‐the‐art
Rotavirus (RV) disease is a leading cause of mortality and morbidity, especially in children under 5 years of age. The introduction of the two oral rotavirus vaccines Rotarix® and RotaTeq® has shown significant reductions in RV‐related mortality, severe RV disease, and hospitalizations. However, some barriers, including a reduced efficacy in low‐income countries, safety issues regarding the intussusception risk, age restrictions on vaccine use, the live‐attenuated nature itself, and the substantial vaccine costs, currently restrict the full potential of RV disease prevention. Therefore, research is now focusing on the implementation of new oral vaccines and the development of parenteral vaccines to overcome these limits. This review provides an overview of the new rotavirus vaccines in clinical development and the ongoing clinical trials on new RV vaccines in the pediatric age.
- 3 February 2020
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (S24) , 58-60
Open AccessRotavirus vaccines in clinical development: Current pipeline and state‐of‐the‐art
Rotavirus (RV) disease is a leading cause of mortality and morbidity, especially in children under 5 years of age. The introduction of the two oral rotavirus vaccines Rotarix® and RotaTeq® has shown significant reductions in RV‐related mortality, severe RV disease, and hospitalizations. However, some barriers, including a reduced efficacy in low‐income countries, safety issues regarding the intussusception risk, age restrictions on vaccine use, the live‐attenuated nature itself, and the substantial vaccine costs, currently restrict the full potential of RV disease prevention. Therefore, research is now focusing on the implementation of new oral vaccines and the development of parenteral vaccines to overcome these limits. This review provides an overview of the new rotavirus vaccines in clinical development and the ongoing clinical trials on new RV vaccines in the pediatric age.
- Open Access
Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view
Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS—Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory and industry representatives. The evidence base for any specific criteria for the design and conduct of efficacy and safety antibiotic trials for children is very limited and will evolve over time as further studies are conducted. The suggestions being put forward here are based on the adult EMA guidance, adapted for neonates and children. In particular, this document provides suggested guidance on the general principles of harmonisation between regulatory and strategic trials, including (1) standardised key inclusion/exclusion criteria and widely applicable outcome measures for specific clinical infectious syndromes (CIS) to be used in CTs on efficacy of antibiotic in children; (2) key components of safety that should be reported in paediatric antibiotic CTs; (3) standardised sample sizes for safety studies. Summarising views from a range of key stakeholders, specific criteria for the design and conduct of efficacy and safety antibiotic trials in specific CIS for children have been suggested. The recommended criteria are intended to be applicable to both regulatory and clinical investigator-led strategic trials and could be the basis for harmonisation in the design and conduct of CTs on antibiotics in children. The next step is further discussion internationally with investigators, paediatric CTs networks and regulators.
Open AccessStandardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view
Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS—Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory and industry representatives. The evidence base for any specific criteria for the design and conduct of efficacy and safety antibiotic trials for children is very limited and will evolve over time as further studies are conducted. The suggestions being put forward here are based on the adult EMA guidance, adapted for neonates and children. In particular, this document provides suggested guidance on the general principles of harmonisation between regulatory and strategic trials, including (1) standardised key inclusion/exclusion criteria and widely applicable outcome measures for specific clinical infectious syndromes (CIS) to be used in CTs on efficacy of antibiotic in children; (2) key components of safety that should be reported in paediatric antibiotic CTs; (3) standardised sample sizes for safety studies. Summarising views from a range of key stakeholders, specific criteria for the design and conduct of efficacy and safety antibiotic trials in specific CIS for children have been suggested. The recommended criteria are intended to be applicable to both regulatory and clinical investigator-led strategic trials and could be the basis for harmonisation in the design and conduct of CTs on antibiotics in children. The next step is further discussion internationally with investigators, paediatric CTs networks and regulators.
- 1 March 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (3) , 251-257
The relationship between Gram-negative colonization and bloodstream infections in neonates: a systematic review and meta-analysis
- 1 March 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (3) , 251-257
The relationship between Gram-negative colonization and bloodstream infections in neonates: a systematic review and meta-analysis
- 7 December 2017
- Published by Springer Nature in Drugs
- Vol. 78 (2) , 231-244
Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000–2016: A Systematic Review and Meta-Analysis
There are very few options to treat multidrug-resistant bacterial infections in children. A major barrier is the duration and complexity of regulatory trials of new antibiotics. Extrapolation of safety data from adult trials could facilitate drug development for children.
- 7 December 2017
- Published by Springer Nature in Drugs
- Vol. 78 (2) , 231-244
Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000–2016: A Systematic Review and Meta-Analysis
There are very few options to treat multidrug-resistant bacterial infections in children. A major barrier is the duration and complexity of regulatory trials of new antibiotics. Extrapolation of safety data from adult trials could facilitate drug development for children.
- Open Access
- 1 November 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (11) , e1066-e1068
Tackling antimicrobial resistance in neonatal sepsis
- 1 November 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (11) , e1066-e1068
Open AccessTackling antimicrobial resistance in neonatal sepsis